Naloxegol in Cancer Opioid-Induced Constipation

Constipation Clinical Trial

Official title:

A Phase II, Randomized, Single Center, Pilot Feasibility Study to Evaluate Naloxegol for Opioid-Induced Constipation in Cancer Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02745353
• Other study ID #: 160121
• Status: Terminated
• Phase: Phase 2
• Start date: May 2016
• Est. completion date: June 22, 2017

Study information

• Verified date: December 2019
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced. Also, the purpose of this study is to compare whether treatment with naloxegol versus usual care has any impact on the number of hospital or clinic visits or telephone calls to the patient's physician that are related to constipation, and to determine the patient's preference for continuing to receive naloxegol as treatment for opioid-induced constipation.

Description:

Opioid-induced constipation (OIC) is a common symptom in patients with cancer-related pain and requires burdensome self-titration of laxatives for prophylaxis and treatment. Consequently, naloxegol may have an important role in this setting. Naloxegol has been evaluated in relieving OIC with cancer patients in a randomized, double blind, placebo-controlled trial over 4 weeks with a 12-week extension phase. However, accrual was challenging and the trial was closed early. Given the complexity of cancer and its treatment, a key first step is to determine if evaluating naloxegol versus standard of care is feasible in the management of OIC in this setting.

Subjects will receive naloxegol 25mg daily or usual care for a 2-week initial treatment period followed by 3-day washout period, then a 2-week crossover treatment period where subjects will receive naloxegol or usual care. Treatment assignment during the initial and crossover treatment periods will be dictated by the randomization arm. Subjects will also have the option to participate in a 12-week extension phase of naloxegol.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: June 22, 2017
• Est. primary completion date: June 22, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults greater than or equal to 18 years old.

• Eastern Cooperative Oncology Group (ECOG) less than or equal to 3.

• Glomerular filtration rate (GFR) greater than or equal to 30 ml/min/1.73m2 by Modification of Diet in Renal Disease (MDRD).

• Corrected serum calcium level less than or equal to 10.5 mg/dL.

• Estimated life expectancy greater than or equal to 6 months.

• Negative pregnancy test prior to initiating study treatment for females of childbearing potential.

Exclusion Criteria:

• Patients receiving the following medications within 3 days of Study Day 1 and/or are planned to receive throughout the duration of the study period: opioid antagonist, mixed antagonist, a strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitor, a moderate CYP3A4 and/or P-gp inhibitor, and/or a strong CYP3A4 inducer.

• Concurrent total parenteral nutrition and/or use of metoclopramide.

• Patients at high risk for bowel perforation.

• Constipation that was not primarily caused by opioids in the investigator's medical opinion.

• A condition that may have affected the permeability of the blood-brain barrier (e.g., known brain metastases, meningeal metastases, brain injury, multiple sclerosis, recent brain injury, uncontrolled epilepsy)

• Patient has clinically active diverticular disease.

• Past medical history of irritable bowel syndrome, signs of active gastrointestinal (GI) bleeding, acute surgical abdomen, bowel stents, indwelling peritoneal catheter, mechanical GI obstruction, fecal impaction, or fecal ostomy.

• Patient has motility/neurologic disorders including autonomic failure (spinal cord lesions, tumor invasion of nerves) and/or poorly controlled endocrine/metabolic disorders (hypercalcemia, hypokalemia, diabetes, hypothyroidism), as determined by the investigator.

• Uncontrolled cancer pain despite analgesic therapy

Related Conditions & MeSH terms

• Constipation

Intervention

Drug:
• naloxegol

Locations

Country	Name	City	State
United States	UCSD Moores Cancer Center	La Jolla	California

Sponsors (2)

Lead Sponsor	Collaborator
Joseph Ma	AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants That Completed Naloxegol 25mg and the Number of Participants That Completed Standard of Care	completion of treatment defined as participants receiving all single daily doses for 2 weeks	4 weeks